Who is sponsoring NCT00557232?

NCT00557232 is sponsored by Instituto de Olhos de Goiania.

What condition does NCT00557232 study?

NCT00557232 studies Glaucoma, Rubeosis Iridis.

What is the status of NCT00557232?

NCT00557232 is currently COMPLETED.

Last reviewed 2011-11-25 · How we verify

The RAVE (Rubeosis Anit-VEgf) Trial, Utilizes Monthly Intravitreal Bevazizumab (Avastin) Injections for 12 Months to See if Total VEGF Blockade Will Prevent Neovascular Glaucoma and Eliminate the Need for Panretinal Photocoagulation in Patients With Ischemic Central Retinal Vein Occlusion

NCT00557232 Phase 4 COMPLETED

Bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) is an anti-VEGF recombinant humanized monoclonal IgG1 antibody used to treat colorectal cancers. Bevacizumab may have a role in treating ocular disorders involving fibrovascular proliferation. To determine whether intraocular bevacizumab decreases rubeosis iridis in patients with neovascular glaucoma.

Details

Lead sponsor	Instituto de Olhos de Goiania
Phase	Phase 4
Status	COMPLETED
Enrolment	25
Start date	2006-11
Completion	2011-11

Conditions

Glaucoma
Rubeosis Iridis

Interventions

bevacizumab

Primary outcomes

Intraocular Bevacizumab (Avastin) for Rubeosis Iridis — Compare results
RI was investigated prospectively by iris biomicroscopy. An expanded informed consent with an off-label use waiver and explanation letter was reviewed with all patients